Browse by author
Lookup NU author(s): Emeritus Professor Philip Home
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.The relationship between baseline fasting C-peptide (FCP) and glucose control was examined in insulin-naïve people with type 2 diabetes inadequately controlled with oral antihyperglycaemic drugs commencing basal insulin glargine 300 U/mL (Gla-300) or 100 U/mL (Gla-100) in the absence of sulfonylurea/glinides. Participants with FCP measurement from the EDITION 3 trial (n = 867) were stratified according to baseline FCP (≤0.40, >0.40-1.20, >1.20 nmol/L); 11.0%, 70.9% and 18.1% contributed to each group. Glycaemic control, body weight, insulin dose and hypoglycaemia were determined at 26 weeks. Glycaemic control (HbA1c, FPG) at 26 weeks was similar in each FCP group between insulins. However, end-of-study insulin dose was greater with higher FCP for both insulins. More people with lower baseline FCP experienced hypoglycaemia with both insulins, but with numerically lower incidence for Gla-300 versus Gla-100 across all FCP groups for all definitions (time periods and levels) of hypoglycaemia. This suggests that Gla-300 might be particularly advantageous for people who are at higher risk of hypoglycaemia.
Author(s): Bolli GB, Landgraf W, Bosnyak Z, Melas-Melt L, Home PD
Publication type: Article
Publication status: Published
Journal: Diabetes, Obesity and Metabolism
Year: 2020
Volume: 22
Issue: 9
Pages: 1664-1669
Print publication date: 01/09/2020
Online publication date: 21/04/2020
Acceptance date: 12/04/2020
Date deposited: 08/06/2020
ISSN (print): 1462-8902
ISSN (electronic): 1463-1326
Publisher: Blackwell Publishing Ltd
URL: https://doi.org/10.1111/dom.14065
DOI: 10.1111/dom.14065
PubMed id: 32314521
Altmetrics provided by Altmetric
